Wang Jie, Yu Gui
Department of Cardiology, Guang'anmen Hospital, Beijing, China.
Chin J Integr Med. 2014 Mar;20(3):163-9. doi: 10.1007/s11655-013-1461-3. Epub 2013 Aug 5.
The prevalence of coronary heart disease (CHD) is increasing, and has been a severe burden on society and family worldwide. New ideas need to be achieved for developing more efficacious and safe therapies to treat CHD. Chinese medicine (CM) uses multicomponent drugs to prevent disease and ameliorate symptoms based on patients' different syndromes. The benefit of CM in CHD has recently been proven by increasing clinical evidence. More importantly, linking CM syndrome differentiation and biomedical diagnosis might provide innovative thinking for treating CHD. According to epidemiological investigations, blood stasis syndrome (BSS) is the major type of syndrome in CHD. Investigating the biomedical mechanisms of BSS of CHD is a topic of CM research. Because the holistic perspective of systems biology is well matched with CM, the application of omics techniques and other integrative approaches appears inherently appropriate. A wide range of omics techniques, including transcriptomics and proteomics, have been used in studies of BSS of CHD to search for a common ground of understanding. These approaches could be useful for understanding BSS of CHD from clinical and biological viewpoints. Nevertheless, current studies mainly contain results from a single approach, and they have not achieved the holistic, systematic and integrative concept of system biology. Therefore, we discuss the progress and challenges in exploring the biomedical mechanisms of BSS of CHD by systems biology approaches. With further development of systems biology, a better platform to study BSS of CHD may be provided, and biomarkers for BSS of CHD and therapeutic targets may be found. The study of BSS of CHD by systems biology approaches will also be beneficial for developing personalized treatment for BSS of CHD patients.
冠心病（CHD）的患病率正在上升，已成为全球社会和家庭的沉重负担。需要有新的思路来开发更有效、更安全的冠心病治疗方法。中医基于患者的不同证候使用多成分药物预防疾病和改善症状。最近越来越多的临床证据证明了中医在冠心病治疗中的益处。更重要的是，将中医证候辨证与生物医学诊断相结合可能为冠心病治疗提供创新思路。根据流行病学调查，血瘀证是冠心病的主要证候类型。研究冠心病血瘀证的生物医学机制是中医研究的一个课题。由于系统生物学的整体观与中医非常契合，组学技术和其他综合方法的应用似乎是内在合适的。包括转录组学和蛋白质组学在内的多种组学技术已被用于冠心病血瘀证的研究，以寻找共同的理解基础。这些方法有助于从临床和生物学角度理解冠心病血瘀证。然而，目前的研究主要包含单一方法的结果，尚未实现系统生物学的整体、系统和综合概念。因此，我们讨论了通过系统生物学方法探索冠心病血瘀证生物医学机制的进展和挑战。随着系统生物学的进一步发展，可能会提供一个更好的研究冠心病血瘀证的平台，并找到冠心病血瘀证的生物标志物和治疗靶点。通过系统生物学方法研究冠心病血瘀证也将有利于为冠心病血瘀证患者制定个性化治疗方案。
